Assertio Therapeutics (ASRT) has disclosed a new risk, in the Debt & Financing category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Assertio Therapeutics remains exposed to pre-closing liabilities from the divested business, including product liability, certain OTREXUP-related obligations, employee matters and unresolved legal issues, which could trigger significant defense, settlement and damage costs. In addition, broad indemnification duties to Cosette—without comparable caps—and potential setoffs against future contingent consideration may create unanticipated cash outflows and weigh on its financial performance and valuation.
Assertio Therapeutics also faces ongoing obligations under ancillary agreements with Cosette, such as transition services and intellectual property arrangements, which can divert management attention from ROLVEDON and the pending merger. Any disputes over the scope or quality of these services could lead to further indemnification or breach-of-contract claims, increasing operational risk and adding uncertainty to its post-transaction integration efforts.
The average ASRT stock price target is $22.40, implying -0.44% downside potential.
To learn more about Assertio Therapeutics’ risk factors, click here.